NCT07252232Phase 3Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Study sponsor: Revolution Medicines, Inc. · RVMD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-05-10Estimated

Enrollment · participants500Estimated

Source updated2026-09-23Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma (PDAC); Resected Pancreatic Adenocarcinoma

Treatments or interventions studied

daraxonrasibDrug

Primary outcomes · main study measures

measure: Disease-Free Survival (DFS) per Investigator; description: DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by Investigator.; timeFrame: Up to approximately 5 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history